Oncology Drug Approval News Flash

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-29T16:45:34.854Z • Permanent link

Morning Glory Sciences, a biotechnology company, announced that its lead candidate, Belzutifan, has been approved by the FDA for the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. This approval is significant as Belzututian was the first SGLT2 inhibitor to demonstrate efficacy in a Phase III clinical trial for RCC. According to the data, Belzutifan reduced the risk of death by 32% compared to the placebo group.

Dr. Herve Guelon, CEO of Morning Glory Sciences, stated that "This milestone marks a major achievement for our company and the RCC community. We are proud to bring a new treatment option to patients with advanced RCC." The approval was granted under the FDA's accelerated approval program, which allows for the expedited review of treatments that demonstrate substantial evidence of efficacy and clinical benefit in a serious or life-threatening disease.

The FDA's decision was based on the results of the Phase III clinical trial, which involved 540 patients with advanced RCC. The trial showed that Belzutifan significantly improved overall survival and reduced the risk of progression of the disease. The FDA's approval is a significant step forward for the development of new treatments for RCC, which is a leading cause of cancer-related deaths worldwide.

The approval of Belzutifan is a major development in the biotech industry, with significant implications for patients with advanced RCC. The treatment is expected to become available in the United States within the next few months, and Morning Glory Sciences plans to submit its marketing application to the European Medicines Agency shortly. The company's stock price surged by over 50% following the announcement, reflecting the excitement and optimism among investors.

Belzutifan's approval is also expected to have a significant impact on the research community, which has been working to develop new treatments for RCC. The treatment's mechanism of action, which involves inhibiting the SGLT2 protein, is believed to offer a new approach to treating the disease. Researchers are already exploring the potential of SGLT2 inhibitors for other types of cancer, and the approval of Belzutifan is likely to accelerate this research.

The FDA's approval of Belzutifan is also a major development for the biotech industry, which has been working to develop new treatments for RCC. The treatment's approval is expected to lead to increased investment in the development of new treatments for the disease, which could ultimately benefit patients and the broader healthcare system.